Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 2, 2026 · Other material event · Financial statements
Inmune Bio, Inc.
8
Other material event
Jun 2, 2026
| ItemItem | Disclosure |
|---|---|
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
Inmune Bio, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. htm PRESS RELEASE DATED JUNE 2, 2026 Exhibit 99. 1 INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Inmune Bio, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
